Article Details

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ...

Retrieved on: 2024-09-14 05:24:04

Tags for this article:

Click the tags to see associated articles and topics

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with .... View article details on hiswai:

Excerpt

(NASDAQ: HALO) ( Halozyme ) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and ...

Article found on: markets.ft.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up